Loading clinical trials...

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS) | Clinical Trials | Clareo Health

WITHDRAWNPHASE2

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Pilot Study of the GLP-1 Agonist, Liraglutide, on Decreasing Parenteral Support Requirements in Short Bowel Patients.

NCT03371862•Imperial College London

View on ClinicalTrials.gov

Summary

Pilot study looking at the effect on Liraglutide in the reduction of parenteral support in patients with short bowel.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Short bowel (≤200cm) as a result of major intestinal resection (e.g. due to injury, volvulus, vascular disease, Crohn's disease).
•2. Jejunostomy patients only
•3. 12 continuous months of parenteral support (PS) dependency prior to enrolment.
•4. PS required at least 3 times per week to meet their caloric, fluid or electrolyte needs due to on-going malabsorption.
•5. Stable PS for at least 4 consecutive weeks immediately prior to first dose of liraglutide. Stability is described as:
•1. Actual PS usage should match prescribed PS;
•2. Baseline 48-hour urine output is 1-2 L/24 hours.
•6. Body mass index ≥ 19.5 kg/m2.
•7. Adequate hepatic and renal function:
•1. Total bilirubin within the normal range;
+4 more criteria

Exclusion Criteria

•Patients \< 18 years of age
•Pregnancy (Female subjects who are not surgically sterile or post menopausal (defined as aged 55 years or older and/or at least 2 years have elapsed since the last menses) or who are not using medically acceptable methods of birth control during and for 30 days after the treatment period. Acceptable methods of contraception would be a barrier form of contraception, oral contraceptive pill, contraceptive injection or implant or intrauterine implanted device.
•Active malignancy
•Previous malignancy within the past 5 years
•History of multiple endocrine neoplasia type 2 (MEN 2)
•Personal history or family history of medullary thyroid cancer
•Raised serum calcitonin (a biomarker for medullary thyroid cancer) at beginning of trial period
•History of cardiac failure
•Concurrent use of diuretics
•Previous history of pancreatitis
+10 more criteria

Locations (1)

St Mark's Hospital

Harrow, United Kingdom

Key Dates

Start Date

October 20, 2017

Primary Completion Date

August 6, 2020

Completion Date

September 30, 2020

Last Updated

August 14, 2020

Conditions

Short Bowel Syndrome

Interventions

Liraglutide Pen Injector [Victoza]

DRUG

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

NCT07197944

Short Bowel Syndrome

View study

RECRUITING

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

NCT05561647

Short Bowel Syndrome (SBS)

View study

RECRUITINGPHASE3

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

NCT06973304

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 14, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS)

Inclusion Criteria

Exclusion Criteria

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

A Survey to Assess Participants' and Physicians' Knowledge When Using GATTEX (Knowledge Assessment Survey)

A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

A 90 Day Observational Study as an Extension to the Phase 3,Open Labeled Exploratory Study of RELiZORB

Registry for Participants With Short Bowel Syndrome

Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition